Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Jiangsu Aidea Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Jiangsu Aidea Pharmaceutical's CEO'su Jie Zhang, Aug2023 tarihinde atandı, in görev süresi 1.17 yıldır. şirketin hisselerinin 0.022% doğrudan sahiptir ve bu hisselerin değeri CN¥ 879.62K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 4.1 yıldır.

Anahtar bilgiler

Jie Zhang

İcra Kurulu Başkanı

CN¥3.0m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.2yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jun 29

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Jun 07

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Mar 01

CEO

Jie Zhang (54 yo)

1.2yrs

Görev süresi

CN¥3,013,500

Tazminat

Mr. Jie Zhang is CEO & President of Jiangsu Aidea Pharmaceutical Co. Ltd. from August 2023 and has been its Director since March 14, 2023. Mr. Zhang was Executive Vice President of Jiangsu Aidea Pharmaceut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jie Zhang	CEO, President & Director	1.2yrs	CN¥3.01m	0.022% CN¥ 879.6k
Jun Wang	VP & Director	5.7yrs	CN¥872.80k	0.66% CN¥ 25.9m
Qi Hong	Senior Vice President	2.8yrs	CN¥1.11m	Veri yok
Ke Yu	VP & Director	4.1yrs	CN¥929.00k	0.0037% CN¥ 144.3k
Guang Rong Wang	VP & Director	1.6yrs	CN¥876.30k	0.016% CN¥ 640.3k
Hong Qin	Vice President	1.5yrs	CN¥2.46m	Veri yok
Yan Liu	Secretary of the Board	1.5yrs	CN¥679.70k	Veri yok

1.6yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: 688488 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jie Zhang	CEO, President & Director	1.6yrs	CN¥3.01m	0.022% CN¥ 879.6k
Jun Wang	VP & Director	5.7yrs	CN¥872.80k	0.66% CN¥ 25.9m
Ke Yu	VP & Director	4.1yrs	CN¥929.00k	0.0037% CN¥ 144.3k
Guang Rong Wang	VP & Director	5.7yrs	CN¥876.30k	0.016% CN¥ 640.3k
Heliang Fu	Chairman	10.8yrs	CN¥1.12m	0.65% CN¥ 25.8m
Zijian Guo	Independent Director	1.1yrs	CN¥29.40k	Veri yok
Heng Yu	Chairman of the Supervisory Board	4.1yrs	Veri yok	1.2% CN¥ 47.5m
Feng Ying He	Supervisor	4.1yrs	Veri yok	Veri yok
Guang Ji Wang	Independent Director	5.4yrs	CN¥100.00k	Veri yok
Xiao Yan Qi	Independent Director	2.6yrs	CN¥100.00k	Veri yok

4.1yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688488 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Jiangsu Aidea Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

Recent updates

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.018 loss in 2Q 2023)

Less than half of directors are independent

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Full year 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.30 loss in FY 2022)

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.30 loss in FY 2022)

Second quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0.11 loss in 2Q 2022)

New major risk - Share price stability

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.02 loss per share (vs CN¥0.045 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 2Q 2021)

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.03 profit in 1Q 2021)

Full year 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.045 loss per share (vs CN¥0.014 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.053 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.01 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.09 in FY 2019)

New 90-day low: CN¥19.66

New 90-day low: CN¥19.86

New 90-day low: CN¥26.00

New 90-day low: CN¥26.80

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş